Condition
Cord Blood Transplant
Total Trials
4
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (3)
Trial Status
Completed2
Withdrawn1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04990323Phase 1Completed
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
NCT04103879Phase 2Completed
US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
NCT03913026Phase 2Active Not Recruiting
UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia
NCT01554254Phase 2WithdrawnPrimary
Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation
Showing all 4 trials